Delving into the Latest Updates on SUN-131(Senju Pharmaceutical Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

SUN 131, SUN-131, SUN-131 TDS

Target

GR

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

NeoplasmsEye Diseases

Active Indication-

Inactive Indication

Chalazion

Originator Organization

Senju Pharmaceutical Co., Ltd.

Active Organization-

Inactive Organization

Senju Pharmaceutical Co., Ltd.

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

This protocol for SUN-131 1.5% TDS is developed for the treatment of chalazion. SUN-131 1.5% TDS is designed for local delivery of a corticosteroid, to the upper or lower eyelid. The purpose of this study is to evaluate the efficacy and safety of SUN-131 1.5% TDS as compared with placebo TDS in the treatment of a chalazion.

Start Date31 Jul 2017

Sponsor / Collaborator

Senju-USA, Inc.

NCT02338648

/ CompletedPhase 2

A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of SUN 131 Transdermal System (TDS) as Compared to Placebo TDS in Adult Patients With a Chalazion

The purpose of this study is to evaluate the efficacy and safety of SUN-131 1.5% TDS as compared with placebo TDS in the treatment of chalazion based on the proportion of subjects that have complete response. Complete response is defined as the absence of any significant clinical signs of a chalazion with possible scaring or skin defects resulting from healing of the chalazion allowed.

Start Date01 Oct 2014

Sponsor / Collaborator

Senju-USA, Inc.

100 Clinical Results associated with SUN-131(Senju Pharmaceutical Co., Ltd.)

Login to view more data

100 Translational Medicine associated with SUN-131(Senju Pharmaceutical Co., Ltd.)

Login to view more data

100 Patents (Medical) associated with SUN-131(Senju Pharmaceutical Co., Ltd.)

Login to view more data

100 Deals associated with SUN-131(Senju Pharmaceutical Co., Ltd.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chalazion	Phase 3	US	Senju Pharmaceutical Co., Ltd.	11 Sep 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03248440 (SUNRISE \| SUN-131-03, CTgov)	Phase 3	Chalazion	263	Placebo TDS (Placebo TDS)	gfcwmiosrq(tilnnskoti) = edwgbayenn xrczqdjzhs (zkkubygyfr, hcboptnibe - gaxzqbmryy) View more	-	05 Aug 2021
				SUN-131 1.5% TDS (SUN-131 1.5% TDS)	gfcwmiosrq(tilnnskoti) = mkdmywsthm xrczqdjzhs (zkkubygyfr, tqndmyqbxf - ltdmbchkpz) View more